These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

86 related articles for article (PubMed ID: 24523109)

  • 1. Irreversible enzyme inhibition kinetics and drug-drug interactions.
    Mohutsky M; Hall SD
    Methods Mol Biol; 2014; 1113():57-91. PubMed ID: 24523109
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Irreversible Enzyme Inhibition Kinetics and Drug-Drug Interactions.
    Mohutsky M; Hall SD
    Methods Mol Biol; 2021; 2342():51-88. PubMed ID: 34272691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. QSAR of cytochrome inhibitors.
    Roy K; Roy PP
    Expert Opin Drug Metab Toxicol; 2009 Oct; 5(10):1245-66. PubMed ID: 19708826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enzyme kinetics of oxidative metabolism: cytochromes P450.
    Korzekwa K
    Methods Mol Biol; 2014; 1113():149-66. PubMed ID: 24523112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of cytochrome P450 enzymes and biochemical aspects of mechanism-based inactivation (MBI).
    Kamel A; Harriman S
    Drug Discov Today Technol; 2013; 10(1):e177-89. PubMed ID: 24050247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reversible mechanisms of enzyme inhibition and resulting clinical significance.
    Ring B; Wrighton SA; Mohutsky M
    Methods Mol Biol; 2014; 1113():37-56. PubMed ID: 24523108
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interindividual variability in inhibition and induction of cytochrome P450 enzymes.
    Lin JH; Lu AY
    Annu Rev Pharmacol Toxicol; 2001; 41():535-67. PubMed ID: 11264468
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure in drug development: the role of inhibition and induction of cytochrome P450 enzymes.
    Hengstler JG; Bolt HM
    Arch Toxicol; 2008 Oct; 82(10):665-6. PubMed ID: 18751968
    [No Abstract]   [Full Text] [Related]  

  • 9. Evaluation of enzyme inhibition kinetics in drug-drug interactions.
    Chen A; Qin X; Tang Y; Liu M; Wang X
    Chem Biol Interact; 2014 Oct; 222():133-4. PubMed ID: 25451570
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically significant cytochrome P-450 drug interactions--a comment.
    Ford NF; Sonnichsen DS
    Pharmacotherapy; 1998; 18(4):890-1; discussion 892-3. PubMed ID: 9692671
    [No Abstract]   [Full Text] [Related]  

  • 11. Simultaneous determination of multiple CYP inhibition constants using a cocktail-probe approach.
    Zientek M; Youdim K
    Methods Mol Biol; 2013; 987():11-23. PubMed ID: 23475664
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generalized proteochemometric model of multiple cytochrome p450 enzymes and their inhibitors.
    Kontijevskis A; Komorowski J; Wikberg JE
    J Chem Inf Model; 2008 Sep; 48(9):1840-50. PubMed ID: 18693719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of drug-drug interactions: concepts and approaches.
    Weaver RJ
    Xenobiotica; 2001; 31(8-9):499-538. PubMed ID: 11569524
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanism-based inactivation of human cytochrome P450 enzymes: strategies for diagnosis and drug-drug interaction risk assessment.
    Venkatakrishnan K; Obach RS; Rostami-Hodjegan A
    Xenobiotica; 2007; 37(10-11):1225-56. PubMed ID: 17968744
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs.
    Crivori P; Poggesi I
    Eur J Med Chem; 2006 Jul; 41(7):795-808. PubMed ID: 16644065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversible Mechanisms of Enzyme Inhibition and Resulting Clinical Significance.
    Ring B; Wrighton SA; Mohutsky M
    Methods Mol Biol; 2021; 2342():29-50. PubMed ID: 34272690
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of CYP-mediated drug interactions in vivo using in vitro data.
    Foti RS; Wahlstrom JL
    IDrugs; 2008 Dec; 11(12):900-5. PubMed ID: 19051152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular basis of P450 inhibition and activation: implications for drug development and drug therapy.
    Szklarz GD; Halpert JR
    Drug Metab Dispos; 1998 Dec; 26(12):1179-84. PubMed ID: 9860924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Interaction of cytochrome P450 3A inhibitors with P-glycoprotein.
    Yasuda K; Lan LB; Sanglard D; Furuya K; Schuetz JD; Schuetz EG
    J Pharmacol Exp Ther; 2002 Oct; 303(1):323-32. PubMed ID: 12235267
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition and induction of human cytochrome P450 enzymes: current status.
    Pelkonen O; Turpeinen M; Hakkola J; Honkakoski P; Hukkanen J; Raunio H
    Arch Toxicol; 2008 Oct; 82(10):667-715. PubMed ID: 18618097
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.